Beike Biotechnology
Beike Biotechnology is a Shenzhen-based biotech company and self-described world's largest adult stem cell provider, treating neurological, vascular, and oncological conditions through 30+ Chinese partner hospitals and international medical tourism, with proprietary MAR/TriTE cancer immunotherapy platforms.
- Company typePrivate
- Founded2005
- HeadquartersShenzhen, China
- Headcount501–1,000
- GTM typeB2B and B2C
- OfferingServices
What Beike Biotechnology does
Beike Biotechnology (Shenzhen Beike Biotechnology Co., Ltd.), founded in July 2005 and headquartered in Shenzhen, China, is a privately held biotechnology company that describes itself as the world's largest adult stem cell provider, focused on the research, development, and clinical translation of adult stem cell therapies and immunotherapies. Its core platform produces umbilical cord blood-derived stem cells (UCBSC) and umbilical cord-derived mesenchymal stem cells (UCMSC), administered at 30+ partner hospitals across China and through international medical tourism channels (notably Better Being Hospital in Bangkok) to treat neurological conditions, spinal cord injuries, cerebral palsy, ALS, multiple sclerosis, vascular diseases, and other chronic or currently incurable illnesses. The proprietary MAR (Major Histocompatibility Antigen Receptor) and TriTE (Tri-functional T cell Engager) platforms underpin a second franchise in cancer immunotherapy, including MAR-T cell therapies, MCAR-T and MCAR-NK product lines, BiAT bi-specific antibodies, and the China-licensed ALT-803 IL-15 superagonist from Altor Bioscience. Affiliated subsidiaries Timmune and Transimmune Biotech (formed through the 2015 acquisition of Nanjing Abingen Biotech) carry the immunotherapy pipeline.
Revenue mechanics are diversified across four streams: per-procedure stem cell supply to domestic partner hospitals, international medical tourism treatments (one reported $50,000 procedure in Thailand), cell banking subscriptions through the Shenzhen Integrated Cell Bank and Jiangsu Stem Cell Bank, and licensing/royalty economics from the immunotherapy portfolio. The company supports operations with 25 GMP-standard laboratories, a 20,000 sqm Taizhou facility storing up to 1 million samples, AABB/ISO/CNAS certifications, ~50 peer-reviewed publications including in Nature, and 700+ employees of whom 60+ hold PhDs from top Chinese universities with prior tenure at Stanford, University of Minnesota, and UCLA. The company has cumulatively treated over 20,500 patients and received over US$6 million in government grants, but does not publicly disclose revenue.
Beike Biotechnology firmographics
Firmographics- Name
- Beike Biotechnology
- Legal name
- Beike Biotechnology Co., Ltd.
- Website
- https://beikebiotech.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Beike Biotechnology is a Shenzhen-based biotech company and self-described world's largest adult stem cell provider, treating neurological, vascular, and oncological conditions through 30+ Chinese partner hospitals and international medical tourism, with proprietary MAR/TriTE cancer immunotherapy platforms.
- Ownership category
- akta.pro rank
Beike Biotechnology industry classification
Industry- Product category
- Regenerative Medicine - Cell Therapy
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), NK Cell Therapies (HLAAABAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where Beike Biotechnology is headquartered
LocationHeadquarters
- HQ city
- Shenzhen
- HQ country
- China
- HQ region
- Asia
Offices3 records
Markets served
Beike Biotechnology business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Stem Cell Therapy Products: Beike provides stem cells to partner hospitals for clinical treatment of patients. The company maintains full oversight over cell manufacturing, from testing of blood products, to cell processing at their laboratories, to delivery of cells for clinical use.
- Cell Banking Services: Stem cell collection, storage and banking services through Shenzhen Integrated Cell Bank and regional cell preparation centers.
- Cell Processing Laboratory Services: Provides cell processing laboratory services to partner hospitals and medical institutions.
- Immunotherapy Products: Development and commercialization of immunotherapy products including ALT-803, CAR-T products, and MAR-based antibody therapies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | — | Stem cell treatment procedure |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels6 records
Beike Biotechnology product offering
Product offeringCore offering
Beike Biotechnology is the world's largest stem cell provider focusing on the research, development, and clinical translation of adult stem cells. The company produces umbilical cord blood-derived and umbilical cord-derived mesenchymal stem cells, providing them to 30+ partner hospitals in China for treatment of neurological, vascular, and degenerative conditions. In addition, Beike develops proprietary immunotherapy products including CAR-T variants (MAR-T), bi-specific antibodies (BiAT), and NK cell therapies (MCAR-NK) using its MAR and TriTE technology platforms, with the licensed ALT-803 IL-15 superagonist for cancer treatment.
Product overview
Beike Biotechnology operates as a biotechnology company offering stem cell therapies and immunotherapies through multiple integrated platforms and services. The core product portfolio includes adult stem cell therapies (umbilical cord blood-derived and umbilical cord-derived mesenchymal stem cells) for treatment of neurological, vascular, and optic conditions. The immunotherapy portfolio includes proprietary MAR and TriTE technology platforms powering CAR-T variants (MAR-T), bi-specific antibodies (BiAT), and NK cell therapies (MCAR-NK). Key products include ALT-803 (IL-15 superagonist licensed from Altor Bioscience), with subsidiaries Timmune and Transimmune developing cell therapies and fusion protein drugs. Supporting infrastructure includes the Shenzhen Integrated Cell Bank for stem cell storage and the Shenzhen Regional Cell Preparation Center for GMP-compliant cell manufacturing. The company has treated over 20,500 patients and provides services to more than 30 partner hospitals in China.
Differentiator
Problem solved
Functional benefit
Products and services
- Umbilical Cord Blood-Derived Stem Cells (UCBSC) Stem cell injections derived from umbilical cord blood containing three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. Used for treatment of conditions including spinal muscular atrophy, ataxia, and optic nerve conditions.
- Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC) Stem cell injections containing a higher percentage of mesenchymal stem cells than UCB stem cell injections. Recommended for multiple sclerosis (MS) and spinal cord injury (SCI) patients. Produces growth factors, differentiates into desired cell types, and modulates the immune system.
- ALT-803 (IL-15 Superagonist) Potent immunotherapeutic agent capable of activating immune cell responses against hematologic and solid tumors and virally infected cells. Licensed from Altor Bioscience for China development and commercialization.
- MAR-T Cell Therapy Variant of CAR-T for adoptive T cell cancer therapy utilizing proprietary TriTE platform and MAR. Results in T cells with improved micro-environment functions, higher number of binding targets with better binding specificity and affinity.
- MCAR-T Series (MAR-based CAR-T) MAR-based CAR-T cell therapy product line with distinct advantage over regular CAR-T in wider spectrum of target binding. Includes MCAR-T/GP100 for solid tumor treatment.
- MCAR-NK Series (MAR-based CAR-NK) MAR-based NK cell therapy product line including MCAR-NK/GP100 for solid tumor treatment with wider spectrum of target binding compared to regular NK cell therapies.
- BiAT Bi-specific Antibody Bi-specific antibody fusion protein drug candidates using MAR as target binding end combined with T cell engagers. Includes BiAT HER2/CD3, CD20/CD3, and EGFR/CD3 for various cancer applications.
- CSF Safe-A Cell Freeze Solution Specially developed for immune cell freezing and storage. Part of laboratory products serving cell therapy and cell banking industry.
- Shenzhen Integrated Cell Bank Stem cell collection, storage and banking services. Collects and stores stem cells from umbilical cord, placenta, fat, deciduous teeth, and adult peripheral blood sources. AABB accredited for cord blood processing, storage, distribution, cell therapy activity, somatic cell processing, storage, and distribution.
- Shenzhen Regional Cell Preparation Center Regional cell preparation center for south China region, located at Beike Biotechnology headquarters. Provides GMP-compliant cell manufacturing services for clinical translation of cell therapy.
- Stem Cell Treatment Services Clinical cell therapy services treating over 20,500 patients since 2005. Provides treatments for neurological conditions (cerebral palsy, spinal cord injury, ALS, multiple sclerosis, ataxia), vascular conditions, optic nerve conditions, and various other conditions. Administered through 30+ partner hospitals in China and through international medical tourism channels including Better Being Hospital in Thailand.
Quantifiable outcome
- Over 20,500 patients treated since 2005
- +6 more outcomes
Companies that use Beike Biotechnology
Customer profileNamed customers7 records
Segments5 records
Ideal customer profiles4 records
Beike Biotechnology technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Beike Biotechnology partnerships and signals
Strategic signalPartnerships
18 partnerships are on record, tiered strategic, core and minor.
- Karolinska Institute (Sweden)strategicDelegation from Sweden's Karolinska Institute visited Beike headquarters to explore medical research cooperation. Focus areas include regenerative medicine, cancer research, and clinical application of cell therapy technology. Both parties seek to strengthen exchanges in basic stem cell research.
- 11 Shenzhen HospitalscoreStrategic partnership through Shenzhen Clinical Translation Platform for Personalized Cell Therapy. Includes Luohu Group Hospital, Shenzhen Second People's Hospital, Shenzhen Maternity & Child Healthcare Hospital, and others.
- Nanjing Abingen Biotech Co. Ltd. (Transimmune Biotech Inc.)strategicAcquired innovative immunotherapy developer with proprietary technologies and products. Led to formation of Transimmune Biotech Inc. as Beike's affiliated company for innovative immunotherapeutic programs including BiAT antibodies and CAR-T products.
- Altor Bioscience CorporationcoreLicense agreement to develop and commercialize ALT-803, Altor's proprietary IL-15 superagonist, in China. Beike participates in Phase 3 clinical trials and manages approval and commercial activities in China. ALT-803 is considered one of the most promising therapeutic agents by National Cancer Institute.
- Tsinghua University (Shenzhen Graduate School)coreEstablished world-class joint laboratory for cell reprogramming and gene engineering research. USD $4 million grant from Shenzhen Municipal Government for equipment. Lab focuses on stem cells, nuclear transfer, reprogramming, and monoclonal antibodies. Staffed by 50+ researchers including 20 renowned Chinese PhDs.
- Biomaster Inc. (Japan)strategicInvestment partnership with Yokohama-based regenerative medicine company specializing in adipose-based stem cell therapies. Beike took significant share and board seat. Biomaster is the only company in Japan authorized to offer stem-cell based therapies publicly.
- Better Being Hospital (Thailand)coreInternational treatment partnership for administering stem cell therapies to international patients. Dr. Torsak leads the collaboration, representing commitment to highest quality clinicians and clinics worldwide.
- Huazhong University of Science and TechnologycoreResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
- Sun Yat-Sen UniversitycoreResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
- Chinese University of Hong KongcoreResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
- Zhengzhou UniversitycoreResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
- Blood Transfusion Institute of Military Medical Science Academy of the PLAcoreResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
- PLA Navy General HospitalcoreResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
- Xijing Hospital of the Fourth Military Medical UniversitycoreResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
- National Innovation Strategic Alliance of Stem Cell and Regenerative Medicine IndustrystrategicBeike is a member of this national alliance. Dr. Xiang (Sean) Hu serves as vice chairman. Jiangsu Beike is the organizer of Jiangsu Provincial Innovation Strategic Alliance of Stem Cell Industry.
- Cerebral Palsy SupportminorPartnership with Cerebral Palsy Support website providing information for parents of children diagnosed with cerebral palsy.
- ECM MedicalminorMarketing partnership with ECM Medical.
- LingolanderminorMarketing partnership with Lingolander.
Scale indicators11 records
Recent moves12 records
Expansion highlights6 records
Beike Biotechnology competitors and assessment
Company assessmentDirect peers
- Athersys: Clinical-stage cell therapy company developing MultiStem (multipotent adult progenitor cell) for stroke, ARDS, and trauma; comparable as a peer using off-the-shelf adult stem cells in regenerative medicine indications.
- Pharmicell: Korean stem cell company with an approved autologous bone marrow MSC therapy (Cartistem) and a bank/clinical-translation model; closely comparable to Beike's cord blood and bone-marrow derived MSC business.
- CARsgen Therapeutics: China-based CAR-T developer with both hematologic and solid-tumor programs; directly comparable to Beike's MCAR-T/GP100 solid-tumor strategy and Chinese regulatory pathway.
- JW Therapeutics: China-based CAR-T developer with an approved CD19 CAR-T product (Carteyva); closely comparable to Beike's MAR-T, MCAR-T, and CAR-T pipeline on geography, modality, and target antigens.
- Medipost: Korean biotech with an approved allogeneic umbilical cord blood MSC product (Cartistem/Cupistem) and a cell banking business; directly comparable to Beike's UCMSC therapy and cord blood banking operations.
- Cellular Biomedicine Group: China-based cell therapy company developing immune-cell and stem cell therapies for cancer and degenerative diseases; directly comparable as a Chinese peer operating in the same regulatory and clinical environment as Beike.
- Mesoblast: Commercial-stage developer of mesenchymal stem cell (MSC) therapies for inflammatory and immune-mediated diseases; directly comparable to Beike's UCMSC franchise on cell type, indications, and scale-up model.
Broad incumbents
- Bristol Myers Squibb: Major oncology company with approved CAR-T products (Breyanzi, Abecma) and active cell therapy development; sets the standard Beike's MAR-T/MCAR-T programs would need to differentiate against in oncology.
- Novartis: Global pharma with the first approved CAR-T (Kymriah) and active cell therapy investment; broad incumbent whose pricing, distribution, and clinical evidence define the bar for new entrants like Beike.
- Bluebird Bio: Established gene and cell therapy company with multiple approved and clinical-stage autologous therapies; relevant as a broad incumbent in cell-based medicine that competes for the same clinical and capital mindshare as Beike.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
Beike Biotechnology social profiles
Digital presenceBeike Biotechnology compliance and trust
Trust signalCompliance6 records
Beike Biotechnology financial estimates
Financial estimateRevenue estimate
Valuation estimate
Beike Biotechnology leadership team
Management profileNumber of profiles
Profiles5 records
Beike Biotechnology subsidiaries and ownership
Company hierarchySubsidiaries6 records
Beike Biotechnology funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Beike Biotechnology M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Beike Biotechnology
What does Beike Biotechnology do?
Beike Biotechnology is the world's largest stem cell provider focusing on the research, development, and clinical translation of adult stem cells. The company produces umbilical cord blood-derived and umbilical cord-derived mesenchymal stem cells, providing them to 30+ partner hospitals in China for treatment of neurological, vascular, and degenerative conditions. In addition, Beike develops proprietary immunotherapy products including CAR-T variants (MAR-T), bi-specific antibodies (BiAT), and NK cell therapies (MCAR-NK) using its MAR and TriTE technology platforms, with the licensed ALT-803 IL-15 superagonist for cancer treatment.
Is Beike Biotechnology a public or private company?
Beike Biotechnology is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Beike Biotechnology founded?
Beike Biotechnology was founded in 2005. It employs 501 to 1,000 people.
Where is Beike Biotechnology based?
Beike Biotechnology is headquartered in Shenzhen, China, in the Asia region.
How does Beike Biotechnology make money?
Four revenue lines are on record. Stem Cell Therapy Products are the primary driver. The others are cell Banking Services, cell Processing Laboratory Services and immunotherapy Products.
Who are Beike Biotechnology's main competitors?
Direct peers on record are Athersys, Pharmicell, CARsgen Therapeutics, JW Therapeutics, Medipost, Cellular Biomedicine Group and Mesoblast. Broad incumbents are Bristol Myers Squibb, Novartis and Bluebird Bio.
Does Beike Biotechnology have an API?
No public API is recorded for Beike Biotechnology.
What industry is Beike Biotechnology in?
Beike Biotechnology's product category is Regenerative Medicine - Cell Therapy. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.